AI Article Synopsis
- Recent studies suggest a potential link between the use of insulin Glargine and cancer, but the findings are largely based on observational data with significant methodological flaws.
- It's difficult to establish a direct cause-and-effect relationship due to confounding factors like obesity, hyperinsulinemia, and smoking that also influence cancer risk.
- The review found several methodological issues in the studies analyzed and concluded that there's insufficient evidence to confirm a definitive association between insulin Glargine and cancer, emphasizing the need for long-term prospective research for clearer insights.
Article Abstract
Recent publications indicate a possible association between newer analogue insulin Glargine and cancer. However all these data were observational in nature and subject to lot of methodological errors. It is practically impossible to derive at a cause and effect relationship based on these observational studies. There are several confounding factors like hyperinsulinemia, obesity and smoking, which independently can be associated with cancer risk. This review looks into the recently published observational studies from the methodological point of view and whether such a negative association can indeed be drawn as a conclusion. Several methodological defects were identified in the process of scrutiny and we concluded it is not possible to conclude that there is an association between Glargine use and cancer. However long-term prospective data is required to come to definite conclusion.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.dsx.2012.03.004 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!